What comes to mind first is the question if Diabetes-medications should be used for weight loss in the first place. Since there is also a shortage, this could mean that a lot of people who actually need it will not be able to get their medication in time. This will be disastrous for the patiënts who really rely on it. Then again, obesity is also a really dangerous epidemic in the general population and can cause a lot of health problems, such as heart failure. Concerns also exist that wealthy patients may have better access, exacerbating social disparities and medicalizing inequality. Secondly, there is a discussion that governments should not subsidize Semaglitude for weight loss, with most arguing against it with personal responsibility. It is suggested that critics find that the government would rather fund ‘a quick fix’, rather than healthy lifestyle choices and good eating habits. This could be harmful to society as a whole, given the amount of obesity we currently have. 

Furthermore, the high cost of Ozempic primarily benefits the pharmaceutical companies that sell it. Lots of debates erupted over whether the market in healthcare is the right thing for the people. This only emphasizes the fact that a quick fix that earns money for certain companies is preferred instead of the slow, healthy lifestyle choices that require time to get used to. A shift from traditional biomedical ethics to a structural ethical framework is advocated. This framework would question the social and economic systems that create obesity and inequality, rather than solely focusing on individual treatment decisions.

Lastly, the usage of medication like this for weight loss could reinforce fat-phobic ideas. Not everyone can have the perfect body, and these companies that advertise Semaglutide for weight loss give the impression that it is possible. There are discussions that obesity should be called a disease, while others are against it due to the medicalisation and stigmatisation of obesity as a whole!